Table 2.
Infection type, treatment strategy, and outcomes.
| Patient | Orthopaedic infection(s) | Date of positive GAS culture | Surgical management | Antibiotic Regimen | Total Antibiotic Duration | ID consult | Initial and final ESR mm/hr) | Initial and final CRP (mg/dL) | Cure at 90 days | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Right leg necrotizing fasciitis, osteomyelitis; prior tibial ORIF | 7/3/2017 | I&D and fasciotomy | 2 weeks of IV vancomycin/piperacillin-tazobactam/clindamycin or IV penicillin, then 4 weeks of PO amoxicillin/clavulanate | 6 weeks | Y | 110, 39 | 42.4, 3.7 | Yes | IVIG X 3 days |
| 2 | Left hand flexor tenosynovitis | 9/18/2018 | I&D | IV Ceftriaxone and metronidazole for 4 days, then PO amoxicillin/clavulanate for 10 days | 2 weeks | Y | 55, not done | 6.3, not done | Yes | |
| 3 | Right hand flexor tenosynovitis | 10/20/2018 | I&D | IV Ampicillin/sulbactam for 3 days, then PO amoxicillin/clavulanate for 2 weeks | 17 days | Y | 101, 47 | 4.2, 0.8 | Yes | |
| 4 | Left foot necrotizing fasciitis and osteomyelitis | 10/24/2018 | I&D, below knee amputation | IV Vancomycin and piperacillin/tazobactam for 5 days, then IV ceftriaxone andclindamycin for 1 week, then PO linezolid for 17 days | 4 weeks | Y | >140, >140 | 33.4, 9.7 | No | |
| 5 | Left foot osteomyelitis | 10/18/2018 | Foot amputation | PO Linezolid for 4 weeks | 4 weeks | Y | 46, not done | 2.4, not done | No | |
| 6 | Right foot osteomyelitis | 11/30/2018 | None | IV Vancomycin and piperacillin/tazobactam for 3 days | 3 days | N | 72, not done | 1.8, not done | No | Patient left against medical advice; had co-infection with P. multocida |
| 7 | Right foot necrotizing fasciitis and osteomyelitis | 11/24/2018 | Foot amputation | IV Vancomycin and piperacillin/tazobactam for 4 days, then IV ceftriaxone and clindamycin for 3 days, then IV ampicillin/sulbactam for 2 weeks | 3 weeks | Y | 85, not done | 30.8, not done | Yes | Co-infection with MSSA |
| 8 | Left hip and femur septic arthritis and osteomyelitis | 12/30/2018 | I&D | IV Vancomycin and ceftriaxone for 1 week, then PO cephalexin for 6 weeks | 7 weeks | Y | 40, not done | 4.5, <0.5 | Yes | |
| 9 | Right ankle prosthetic joint infection | 12/12/2018 | I&D and prosthesis removal with antibiotic bead placement, followed by revision | IV Ceftriaxone and clindamycin for 1 week, then IV ceftriaxone alone for 5 weeks | 6 weeks | Y | 114, 41 | 17.3, 0.7 | Yes | |
| 10 | Right foot osteomyelitis | 12/3/2018 | Foot amputation | IV Vancomycin and ciprofloxacin for 5 days, then IV cefazolin for 1 week | 12 days | Y | 35, not done | 3.5, not done | No | Co-infection with MSSA |
| 11 | Right leg necrotizing fasciitis and osteomyelitis | 12/2/2018 | Below knee amputation | IV Vancomycin, clindamycin and meropenem for 11 days | 11 days prior to in-hospital death | Y | 27, not done | 31.2, not done | No | Co-infection with P.stuartii, deceased within 90 days from fungemia |
| 12 | Right knee prosthetic joint infection | 2/19/2019 | I&D, one-stage prosthesis revision | IV Ceftriaxone and clindamycin for 1 week, then IV ceftriaxone alone for 5 weeks, then PO cephalexin chronic suppression | 6 weeks, then chronic suppression | Y | 53, 28 | 3.4, 1.5 | Yes | Suppressive cephalexin for ≥1 year due to immuno-suppressive therapy for RA |
| 13 | Right ankle achilles tenosynovitis overlying prior ORIF site | 4/11/2019 | I&D, antibiotic beads placement, followed by skin graft | Vancomycin and piperacillin/tazobactam for 3 days, then cefazolin for 3 days then linezolid for 2 weeks | 3 weeks | Y | 30, not done | 0.9, not done | Yes | Co-infection with MSSA |
IV: intravenous, PO: oral, ESR: erythrocyte sedimentation rate, I&D: incision and drainage, IVIG: intravenous immunoglobulin, MSSA: methicillin-susceptible S. aureus, RA: rheumatoid arthritis.